July 20, 2017
The Interim Recommendation made by the National Drug Scheduling Advisory Committee (NDSAC) on June 19, 2017, subsequent to their meeting of June 11, 2017, was finalized effective July 20, 2017. The final recommendation is as follows:
· minoxidil, when sold in preparations for topical use in adults in concentrations of 5% or less, be granted unscheduled status, for human use only
Final approval of the interim recommendation was made by NAPRA's Executive Committee, in consideration of comments received during the 30-day review period. The National Drug Schedules will be revised accordingly.